SEARCH THE OnBioVC DATABASE:
OnBioVC NEWS:

- OnBioVC 4Q11 Trend Analysis, now available
- OnBioVC 1Q12 White Paper, now available
- OnBioVC 1Q12 Trend Analysis, coming soon

30

Mar

2009

Neuraltus Pharmaceuticals, Inc.: Series A $17M

Posted in I - Series A, Q - 1Q09, R - WEST, X - ALS, X - Dyskinesia, X - Neurology, XX - CA

Neuraltus Pharmaceuticals (Menlo Park, CA) a preclinical-stage developer of small-molecule drugs focused on Amyotropic Lateral Sclerosis and dyskinesia, closed a $17M Series A financing. Participants include Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners.

Venture Capital Investors
5AM Ventures Advanced Technology Ventures Alta Partners Amgen Ventures ARCH Venture Partners Atlas Venture Bay City Capital Bessemer Venture Partners Canaan Partners Clarus Ventures Delphi Ventures Domain Associates Edmond de Rothschild Investment Partners Flagship Ventures Forbion Capital Partners HBM Bioventures Healthcare Ventures HLM Venture Partners Interwest Partners Investor Growth Capital Johnson & Johnson Development Corp. Kleiner Perkins Latterell Venture Partners Lilly Ventures Mohr Davidow Ventures MPM Capital New Enterprise Associates New Leaf Venture Partners Novartis Venture Fund Novo Ventures OrbiMed Pappas Ventures Polaris Venture Partners Prospect Venture Partners Quaker BioVentures Sanderling Ventures Sofinnova Partners Sofinnova Ventures SR One SV Life Sciences Third Rock Ventures TPG Biotech TVM Capital Venrock Versant Ventures

OnBioVC Friends

FluidicMEMES
IguanaBio
EyeOnFDA
Patent Baristas
Pharma's Cutting Edge
MedTechIQ
The Antibody Blog
BioJobBlog

OnBioVC Partners